EMA Guideline on Biosimilar Medicines

This document describes the regulatory framework for biosimilar medicines in the European Union, including their definition, development and approval procedures, and the safety of biosimilar medicines.


EMA Guideline on Biosimilar Medicines - cover page
Brand
EMA
Category
Health Care
Document type
Product Leaflet
Language
Italian
Pages
38
File format
PDF
File size
1.9 MB
Published
25 November, 2023
Updated
25 November, 2023
MD5 checksum
09CCCA663896BD7B9DADC4658EB9D14B

About this manual

This document, jointly developed by the European Medicines Agency (EMA) and the European Commission, provides healthcare professionals with scientific and regulatory information on biosimilar medicines. It explains how biosimilars are developed, authorized, and monitored for safety in the EU. The guide emphasizes that biosimilars are highly similar to already-approved reference biologics and are subject to the same quality, safety, and efficacy standards. It also addresses safety monitoring, extrapolation of indications, and the role of national authorities in interchangeability decisions.

The document includes sections on the definition of biosimilars, regulatory procedures, immunogenicity, safety monitoring, traceability, and patient communication. It highlights that biosimilars have been safely used in the EU since 2006 and that their approval relies on comprehensive comparability studies and scientific evidence. This manual is written in Italian.

What's inside

  • Medicinali biologici: introduzione
  • Medicinali biosimilari: definizione e caratteristiche
  • Sviluppo e autorizzazione dei medicinali biosimilari nell'UE
  • Immunogenicità
  • Estrapolazione
  • Sicurezza dei medicinali biosimilari
  • Tracciabilità
  • Dati compresi nelle informazioni prescrittive
  • Implicazioni della disponibilità dei medicinali biosimilari
  • Comunicare con i pazienti in merito ai medicinali biosimilari

Frequently asked questions

What are biosimilar medicines?

Biosimilar medicines are highly similar to an already-approved biologic medicine (the 'reference medicine') in all essential aspects.

Are biosimilar medicines as safe and effective as the reference medicines?

Yes, biosimilar medicines authorized by the EMA have the same safety and efficacy as the reference medicines for the authorized indications.

Who regulates biosimilar medicines in the EU?

The European Medicines Agency (EMA) and the European Commission jointly regulate biosimilar medicines in the EU.

Do biosimilar medicines require special safety monitoring?

No, biosimilar medicines are monitored for safety through the same pharmacovigilance system as all other medicines in the EU.

Download PDF (1.9 MB)

More EMA Manuals


View all EMA manuals →